可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function[J]. Circulation, 2002, 105(11):1387-1393.
[2] 戴闺柱.慢性心力衰竭治疗的现代概念[J]. 中华心血管病杂志, 2000, 28(1):75-78.
[3] Stanley WC. Changes in cardiac metabolism: a critical step from stable gina to ischemic cardiomyopathy[J]. Eur Heart J Suppl, 2001, 3(Suppl O):O2-O7.
[4] Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism feom fatty acid oxidatiom to glucose by inhibiting mitochondrial long_chain 3_ketoacyl AS thiolase[J]. Circ Res, 2000, 86(5):580-588.
[5] Renaud JF. Internal pH, Na+ , and Ca++ regulation by trimetazidine during cardiac cell acidosis[J]. Cardiovasc Drugs Ther, 1988, 1(6):677-686.
[6] Aussedat J, Ray A, Kay L, et al. Improvrment of long_term preservation of isolated arrested rat heart:beneficial effect of the antiischemic agent trimetazidine[J]. J Cardiovasc Pharmacol, 1993, 21(1):128-135.
[7] Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy[J]. Eur Heart J, 2001, 22(23):2164-2170.